NEXI1EUR
Neximmune, Inc.
A clinical-stage biotech company working on cell therapies to treat cancer, Neximmune grows immune cells called NK cells in the lab and engineers them to attack tumors. The technology grew out of research at the National Cancer Institute, and the company was co-founded in 2015 by NIH physician-scientist Richard Childs, who spent his career studying natural killer cells. The name itself pairs "next" with "immune," hinting at its bet on the body's own defenders.
CUSIP: 65344D109HealthcareUS1 holder
Total Value
$2.7K
Total Shares
10.9K
Net Share Change
-958.1K
Activity
1 selling
Investor
Value
Shares
Weight
Change
